Responses to commentary on ‘Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis’ (Int J Surg 2022;106:106929)

Detalles Bibliográficos
Autores principales: Wang, Zhaoyang, Wang, Yuanyong, Feng, Yingtong, Yan, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389394/
https://www.ncbi.nlm.nih.gov/pubmed/37132181
http://dx.doi.org/10.1097/JS9.0000000000000262
_version_ 1785082290281381888
author Wang, Zhaoyang
Wang, Yuanyong
Feng, Yingtong
Yan, Xiaolong
author_facet Wang, Zhaoyang
Wang, Yuanyong
Feng, Yingtong
Yan, Xiaolong
author_sort Wang, Zhaoyang
collection PubMed
description
format Online
Article
Text
id pubmed-10389394
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-103893942023-08-01 Responses to commentary on ‘Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis’ (Int J Surg 2022;106:106929) Wang, Zhaoyang Wang, Yuanyong Feng, Yingtong Yan, Xiaolong Int J Surg Correspondence Lippincott Williams & Wilkins 2023-05-03 /pmc/articles/PMC10389394/ /pubmed/37132181 http://dx.doi.org/10.1097/JS9.0000000000000262 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Correspondence
Wang, Zhaoyang
Wang, Yuanyong
Feng, Yingtong
Yan, Xiaolong
Responses to commentary on ‘Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis’ (Int J Surg 2022;106:106929)
title Responses to commentary on ‘Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis’ (Int J Surg 2022;106:106929)
title_full Responses to commentary on ‘Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis’ (Int J Surg 2022;106:106929)
title_fullStr Responses to commentary on ‘Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis’ (Int J Surg 2022;106:106929)
title_full_unstemmed Responses to commentary on ‘Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis’ (Int J Surg 2022;106:106929)
title_short Responses to commentary on ‘Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis’ (Int J Surg 2022;106:106929)
title_sort responses to commentary on ‘efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis’ (int j surg 2022;106:106929)
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389394/
https://www.ncbi.nlm.nih.gov/pubmed/37132181
http://dx.doi.org/10.1097/JS9.0000000000000262
work_keys_str_mv AT wangzhaoyang responsestocommentaryonefficacyandsafetyofneoadjuvantimmunotherapyinsurgicallyresectableesophagealcancerasystematicreviewandmetaanalysisintjsurg2022106106929
AT wangyuanyong responsestocommentaryonefficacyandsafetyofneoadjuvantimmunotherapyinsurgicallyresectableesophagealcancerasystematicreviewandmetaanalysisintjsurg2022106106929
AT fengyingtong responsestocommentaryonefficacyandsafetyofneoadjuvantimmunotherapyinsurgicallyresectableesophagealcancerasystematicreviewandmetaanalysisintjsurg2022106106929
AT yanxiaolong responsestocommentaryonefficacyandsafetyofneoadjuvantimmunotherapyinsurgicallyresectableesophagealcancerasystematicreviewandmetaanalysisintjsurg2022106106929

Ejemplares similares